Hikma Pharmaceuticals PLC 2020 AR2
The report highlights Hikma Pharmaceuticals PLC's strong performance in 2020, with core Group revenue growing 6% to $2.3 billion and core Group operating profit increasing 11% to $566 million. The company successfully navigated the COVID-19 pandemic, maintaining the supply of vital medicines and partnering to manufacture remdesivir. Hikma also made progress on its ESG strategy, aligning with TCFD recommendations and reducing Scope 1 and 2 greenhouse gas emissions by 0.4% year-on-year. Additionally, the company launched 154 new products globally and completed a significant share buyback.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2020
Type: AR2
Pages: 93
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals PLC's strong performance in 2020, with core Group revenue growing 6% to $2.3 billion and core Group operating profit increasing 11% to $566 million. The company successfully navigated the COVID-19 pandemic, maintaining the supply of vital medicines and partnering to manufacture remdesivir. Hikma also made progress on its ESG strategy, aligning with TCFD recommendations and reducing Scope 1 and 2 greenhouse gas emissions by 0.4% year-on-year. Additionally, the company launched 154 new products globally and completed a significant share buyback.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees